{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:05:55Z","timestamp":1791479155470,"version":"4.3.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/cco.0000000000000053","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T08:42:24Z","timestamp":1389948144000},"page":"171-181","source":"Crossref","is-referenced-by-count":23,"title":["Systemic treatment of malignant pleural mesothelioma"],"prefix":"10.1097","volume":"26","author":[{"given":"Daniel C.","family":"Christoph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried E.E.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000339259","article-title":"Malignant pleural mesothelioma: from the bench to the bedside.","volume":"83","author":"Astoul","year":"2012","journal-title":"Respiration"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma.","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"R7-8-20210128","first-page":"533","article-title":"What is the survival after surgery for localized malignant pleural mesothelioma Interact Cardiovasc Thorac S","volume":"16","author":"Gelvez-Zapata","year":"2013","journal-title":"urg"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s004280050388","article-title":"Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.","volume":"435","author":"Konig","year":"1999","journal-title":"Virchows Arch"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E","article-title":"Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo.","volume":"178","author":"Langerak","year":"1996","journal-title":"J Pathol"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabinecisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group.","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma.","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.","volume":"28","author":"Gregorc","year":"2010","journal-title":"J Clin Oncol"},{"key":"R29-8-20210128","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAFMEKERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"R30-8-20210128","first-page":"2178","article-title":"PTK787ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer Res"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/1078-0432.CCR-11-0937","article-title":"Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.","volume":"17","author":"Rischin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.","volume":"7","author":"Fennell","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","article-title":"Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).","volume":"49","author":"OBrien","year":"2013","journal-title":"Eur J Cancer"},{"key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1200\/JCO.2012.42.1784","article-title":"Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.","volume":"31","author":"Szlosarek","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 9","key":"R37-8-20210128","first-page":"1522D","article-title":"A multicenter phase II clinical trial of the chimeric antimesothelin monoclonal antibody amatuximab in combination with chemotherapy for frontline therapy of malignant pleural mesothelioma: updated clinical outcomes and correlative studies.","volume":"23","author":"Reck","year":"2012","journal-title":"Ann Oncol"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"R42-8-20210128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"R43-8-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.6004\/jnccn.2012.0007","article-title":"Novel therapies in phase II and III trials for malignant pleural mesothelioma.","volume":"10","author":"Zauderer","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"R44-8-20210128","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","article-title":"Malignant mesothelioma: new insights into a rare disease.","volume":"39","author":"Remon","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ccm.2012.12.005","article-title":"Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.","volume":"34","author":"Haas","year":"2013","journal-title":"Clin Chest Med"},{"key":"R46-8-20210128","first-page":"508","article-title":"Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.","volume":"1","author":"Nowak","year":"2012","journal-title":"Ann Cardiothorac Surg"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:34Z","timestamp":1620950134000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201403000-00008"}},"subtitle":["new agents in clinical trials raise hope of relevant improvements"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000053","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}